Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal 4SCAR19U T Cell Therapy in B Cell Malignancies
NCT05995015Phase 1Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 4SCAR19U in B-cell malignancy, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of 4SCAR19U CAR-T cells infusion at 24 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
4SCAR19U
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT05995015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995015.